TREVENA INC (TRVN) Stock Price & Overview
NASDAQ:TRVN • US89532E2081
Current stock price
The current stock price of TRVN is 2.5 USD. Today TRVN is down by -45.71%. In the past month the price decreased by -50.98%. In the past year, price decreased by -82.14%.
TRVN Key Statistics
- Market Cap
- 2.125M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -16.38
- Dividend Yield
- N/A
TRVN Stock Performance
TRVN Stock Chart
TRVN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TRVN. When comparing the yearly performance of all stocks, TRVN is a bad performer in the overall market: 98.56% of all stocks are doing better.
TRVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TRVN. Both the profitability and financial health of TRVN have multiple concerns.
TRVN Earnings
On August 8, 2024 TRVN reported an EPS of -5.79 and a revenue of 283.00K. The company beat EPS expectations (22.51% surprise).
TRVN Forecast & Estimates
8 analysts have analysed TRVN and the average price target is 102 USD. This implies a price increase of 3980% is expected in the next year compared to the current price of 2.5.
For the next year, analysts expect an EPS growth of -916.33% and a revenue growth -95.22% for TRVN
TRVN Groups
Sector & Classification
TRVN Financial Highlights
Over the last trailing twelve months TRVN reported a non-GAAP Earnings per Share(EPS) of -16.38. The EPS decreased by -265.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -264.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TRVN Ownership
TRVN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TRVN
Company Profile
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2014-01-31. The firm has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
Company Info
IPO: 2014-01-31
TREVENA INC
955 Chesterbrook Boulevard, Suite 110
Chesterbrook PENNSYLVANIA 19087 US
CEO: Carrie L. Bourdow
Employees: 23
Phone: 16103548840
TREVENA INC / TRVN FAQ
Can you describe the business of TREVENA INC?
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2014-01-31. The firm has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
What is the stock price of TREVENA INC today?
The current stock price of TRVN is 2.5 USD. The price decreased by -45.71% in the last trading session.
What is the dividend status of TREVENA INC?
TRVN does not pay a dividend.
What is the ChartMill rating of TREVENA INC stock?
TRVN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists TRVN stock?
TRVN stock is listed on the Nasdaq exchange.
Can you provide the number of employees for TREVENA INC?
TREVENA INC (TRVN) currently has 23 employees.
What is TREVENA INC worth?
TREVENA INC (TRVN) has a market capitalization of 2.13M USD. This makes TRVN a Nano Cap stock.